Erik De Clercq


Affiliation: Katholieke Universiteit Leuven
Country: Belgium


  1. request reprint
    De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008;13:393-416 pubmed
  2. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobilâ„¢) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther. 2010;128:509-18 pubmed publisher
    ..e. AMD11070, AMD3465, KRH-3955, T-140, and 4F-benzoyl-TN14003), primarily as potential anti-HIV agents. They are all strong CXCR4 antagonists. Their role in stem cell mobilization remains to be assessed. ..
  3. request reprint
    De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol. 2007;73:911-22 pubmed
    ..e. PMPO-DAPy, PMEO-DAPy, HPMPO-DAPy) and cyclic nucleoside phosphonates (i.e. PMDTA, PMDTT, GS9148) have been accredited with an antiviral potency and selectivity similar to those of cidofovir, adefovir and/or tenofovir. ..
  4. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009;77:1655-64 pubmed publisher
  5. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem Pharmacol. 2011;82:99-109 pubmed publisher
  6. De Clercq E. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem Pharmacol. 2012;84:241-8 pubmed publisher
  7. De Clercq E. Human viral diseases: what is next for antiviral drug discovery?. Curr Opin Virol. 2012;2:572-9 pubmed publisher
    ..Yet, new drugs are at the horizon for the treatment of herpes simplex virus (HSV), varicella-zoster virus (VZV), poxvirus, hepatitis B virus (HBV), influenza and enveloped viruses-at-large. ..
  8. De Clercq E. Antivirals: past, present and future. Biochem Pharmacol. 2013;85:727-44 pubmed publisher
  9. De Clercq E. Chemotherapy of respiratory syncytial virus infections: the final breakthrough. Int J Antimicrob Agents. 2015;45:234-7 pubmed publisher
    ..A new antiviral, GS-5806, which interferes with virus-cell fusion, has proven efficacious in experimental RSV infections in adults. ..

More Information


  1. request reprint
    De Clercq E. Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential. Curr Med Chem. 2015;22:3866-80 pubmed
  2. De Clercq E. Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions. Med Res Rev. 2010;30:667-707 pubmed publisher
  3. De Clercq E. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?. Med Res Rev. 2012;32:765-85 pubmed publisher
    ..Third, Truvada can be used prophylactically to prevent transmission of HIV infection. And fourth, to prevent sexual HIV transmission, tenofovir could also be used topically (i.e., as a vaginal gel). ..
  4. De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol. 2015;93:1-10 pubmed publisher
  5. De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010;10:507-15 pubmed publisher
    ..Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one. ..